

Navicixizumab

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

п		$\overline{}$	VI.	$\neg \Box$			AΤ	1/	71	VΙ
н	1)	\vdash	I/I	- 1	\vdash	1 (\triangle	1 () I	ΛI.

Name

Navicixizumab

Accession Number

DB12634

Type

Biotech

Groups

Investigational

Biologic Classification

Protein Based Therapies Monoclonal antibody (mAb)

Description

Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).

Protein chemical formula

Not Available

	Q	
Sequences		
Not Available		
Synonyms		
Not Available		
External IDs ①		
OMP 305 B83 / OMP 305B83 / OMP-305B83		
Categories		
Not Available		
UNII		
1W14T9L25W		
CAS number		
1638338-43-8		
PHARMACOLOGY		
Indication		
Not Available		
Pharmacodynamics		
Not Available		
Mechanism of action		
Not Available		
Absorption		
Not Available		

		Q	
Protein binding			
Not Available			
Metabolism			
Not Available			
Route of elimination			
Not Available			
Half life			
Not Available			
Clearance			
Not Available			
Toxicity			
Not Available			
Affected organisms			
Not Available			
Pathways			
Not Available			
Pharmacogenomic Effects	ADRs ()		
Not Available			
INTERACTIONS			
Drug Interactions ①			
Not Available			



REFERENCES

General References

Not Available

External Links

PubChem Substance

347911355

CLINICAL TRIALS

Clinical Trials (1)

Search

PHASE ↑↓	STATUS ↑↓	PURPOSE ↑↓	CONDITIONS ↑	COUNT ↑↓
1	Completed	Treatment	Advanced Solid Tumor Malignancies	1
1	Recruiting	Treatment	Cancer Ovaries / Cancer Peritoneal / Fallopian Tube Cancer	1
1	Recruiting	Treatment	Metastatic Colorectal Cancers	1

Showing 1 to 3 of 3 entries

< >

PHARMACOECONOMICS


Manufacturers

Not Available

Packagers

Not Available

		Q	
Not Available			
Patents			
Not Available			
PROPERTIES			
State			
Not Available			
Experimental Properties			
Not Available			
TAXONOMY			
Description			
Not Available			
Kingdom			
Organic Compounds		 	
Super Class			
Organic Acids		 	
Class			
Carboxylic Acids and Deriv	vatives	 	
Sub Class			
Amino Acids, Peptides, an	d Analogues	 	
Direct Parent			



Not Available

Drug created on October 20, 2016 17:21 / Updated on November 02, 2018 07:27

About

About DrugBank

DrugBank Blog

Wishart Research Group

Terms of Use

Privacy Policy

Support

FAQ

Help

Email Support

Commercial Products

API Pricing

API Docs

Data Licenses

Support



research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome British Columbia**, and **Genome Canada**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by **OMx Personal Health Analytics, Inc.** Designed by **Educe Design & Innovation Inc.**











